{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:55:59Z","timestamp":1771232159903,"version":"3.50.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Haemophagocytic lymphohistiocytosis (HLH) is a cytokine-driven inflammatory syndrome caused by uncontrolled hypersecretion of inflammatory cytokines. Conventional first-line treatment for HLH included HLH-94 and HLH-2004 regimens. However, quite a few patients do not respond to treatment or cannot tolerate intensive chemotherapy. We reported two cases of HLH, one caused by natural killer (NK)\/T-cell lymphoma and another associated with missense variants in the <jats:italic>perforin 1<\/jats:italic> gene. They both received the ruxolitinib plus dexamethasone protocol and had a rapid response to treatment without obvious adverse effects. Our report indicates that treatment with ruxolitinib plus dexamethasone might be a potential option for HLH, and clinical trials warrant further investigation. In addition, the detection of HLH-related genes is necessary for the identification of late-onset familial HLH in certain settings.<\/jats:p>","DOI":"10.3389\/fonc.2023.1054175","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T06:07:10Z","timestamp":1677737230000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Case report: Ruxolitinib plus dexamethasone as first-line therapy in haemophagocytic lymphohistiocytosis"],"prefix":"10.3389","volume":"13","author":[{"given":"Lin","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-ying","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-jia","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhou","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000004581","article-title":"Treatment and mortality of hemophagocytic lymphohistiocytosis in adult critically ill patients: a systematic review with pooled analysis","volume":"11","author":"Knaak","year":"2020","journal-title":"Crit Care Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1182\/blood-2011-06-356261","article-title":"Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: Long-term results of the HLH - 94 treatment protocol","volume":"17","author":"Trottestam","year":"2011","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","article-title":"Confirmed efficacy of etoposide and dexamethasone in HLH treatment: Long - term results of the cooperative HLH - 2004 study","volume":"25","author":"Bergsten","year":"2017","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30156-5","article-title":"Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: An open-label, single-centre, pilot trial","volume":"12","author":"Ahmed","year":"2019","journal-title":"Lancet Haematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.222471","article-title":"Ruxolitinib for refractory\/relapsed hemophagocytic lymphohistiocytosis","volume":"5","author":"Wang","year":"2020","journal-title":"Haematologica"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1182\/blood.2021014860","article-title":"A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis","volume":"24","author":"Zhang","year":"2022","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/10600280221134719","article-title":"A review of current and emerging therapeutic options for hemophagocytic lymphohistiocytosis","volume":"9","author":"Summerlin","year":"2022","journal-title":"Ann Pharmacother"},{"key":"B8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"2","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/pbc.24188","article-title":"Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab","volume":"1","author":"Marsh","year":"2013","journal-title":"Pediat Blood Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"19","author":"Locatelli","year":"2020","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.614704","article-title":"Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis","volume":"12","author":"Keenan","year":"2021","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-684399","article-title":"Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis","volume":"13","author":"Das","year":"2016","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1182\/bloodadvances.2017007526","article-title":"Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis","volume":"19","author":"Broglie","year":"2017","journal-title":"Blood Adv"},{"key":"B14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1053\/j.seminhematol.2018.07.006","article-title":"Low dose ruxolitinib plus HLH-94 protocol: A potential choice for secondary HLH","volume":"1","author":"Wang","year":"2020","journal-title":"Semin Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15274","article-title":"How I treat primary haemophagocytic lymphohistiocytosis","volume":"2","author":"Marsh","year":"2018","journal-title":"Br J Haematol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4131","DOI":"10.1182\/bloodadvances.2019000898","article-title":"Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1\/2 inhibitor ruxolitinib","volume":"23","author":"Goldsmith","year":"2019","journal-title":"Blood Adv"},{"key":"B17","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.hemonc.2017.07.002","article-title":"Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report","volume":"3","author":"Sin","year":"2019","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1007\/s00432-020-03301-y","article-title":"Ruxolitinib combined with doxorubicin, etoposide, and dexamethasone for the treatment of the lymphoma-associated hemophagocytic syndrome","volume":"11","author":"Zhou","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26264","article-title":"Clinical presentation and outcome of pediatric patients with hemophagocytic lymphohistiocytosis in China: a retrospective multicenter study","volume":"4","author":"Xu","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01902","article-title":"Epstein-Barr Virus and hemophagocytic lymphohistiocytosis","volume":"8","author":"Marsh","year":"2018","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jcv.2018.03.001","article-title":"Primary Epstein - Barr virus infection","volume":"102","author":"Dunmire","year":"2018","journal-title":"J Clin Virol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13102","article-title":"Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: Impact of triggering disease and early treatment with etoposide","volume":"1","author":"Arca","year":"2015","journal-title":"Br J Haematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.04.034","article-title":"Reactive hemophagocytic syndrome in adults: A retrospective analysis of 162 patients","volume":"11","author":"Riviere","year":"2014","journal-title":"Am J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.blre.2016.05.001","article-title":"Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: A systematic scoping review","volume":"6","author":"Hayden","year":"2016","journal-title":"Blood Rev"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0902-y","article-title":"Identification of clinical features of lymphoma-associated hemophagocytic syndrome (LAHS): an analysis of 69 patients with hemophagocytic syndrome from a single-center in central region of China","volume":"4","author":"Li","year":"2014","journal-title":"Med Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2020.10.004","article-title":"Lymphohistiocytosis type 2 and chronic active Epstein-Barr virus in adulthood","volume":"3","author":"Godby","year":"2021","journal-title":"Am J Med Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"25213","DOI":"10.1074\/jbc.M115.668384","article-title":"Structural basis for Ca2+ - mediated interaction of the perforin C2 domain with lipid membranes","volume":"42","author":"Yagi","year":"2015","journal-title":"J Biol Chem"},{"key":"B28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"ACMG laboratory quality assurance committee. standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/humu.23626","article-title":"ClinGen sequence variant interpretation working group (ClinGen SVI). recommendations for interpreting the loss of function PVS1 ACMG\/AMP variant criterion","volume":"39","author":"Abou Tayoun","year":"2018","journal-title":"Hum Mutat"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.00126","article-title":"Neurologic manifestations as initial clinical presentation of familial hemophagocytic lymphohistiocytosis Type2 due to PRF1 mutation in Chinese pediatric patients","volume":"11","author":"Feng","year":"2020","journal-title":"Front Genet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00432-020-03139-4","article-title":"Hemophagocytic lymphohistiocytosis in adults: Collaborative analysis of 137 cases of a nationwide German registry","volume":"146","author":"Birndt","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1182\/blood-2014-05-573105","article-title":"Synergistic defects of different molecules in the cytotoxic pathway leads to clinical familial hemophagocytic lymphohistiocytosis","volume":"124","author":"Zhang","year":"2014","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1054175\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T14:53:42Z","timestamp":1678200822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1054175\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":32,"alternative-id":["10.3389\/fonc.2023.1054175"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1054175","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,2]]},"article-number":"1054175"}}